Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GlaxoSmithKline Pharmaceuticals Ltd.

http://www.gsk-india.com

Latest From GlaxoSmithKline Pharmaceuticals Ltd.

Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs

GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.

Research & Development Clinical Trials

GSK Is Third Major Inhaler Maker To Cap Copays; Will Teva Follow?

It might make sense from a competitive standpoint for Teva to join the trend. That’s the way it happened in the insulin category.

Reimbursement Pricing Strategies

GSK Is Third Major Inhaler Maker To Cap Copays; Will Teva Follow?

It might make sense from a competitive standpoint for Teva to join the trend. That’s the way it happened in the insulin category.

Reimbursement Pricing Strategies

Boosting Complex Innovative Designs In Clinical Trials: What The Pilots Show

Lilly representative suggests having more informal communication with FDA and consistent feedback across divisions. The firm had a positive experience participating in CID pilot with master protocol for chronic pain therapies.

Clinical Trials Research & Development
See All

Company Information

UsernamePublicRestriction

Register